Day One Appoints Jaa Roberson as Chief People Officer
September 13, 2021 07:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Appoints Scott Garland to Board of Directors
August 17, 2021 07:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Reports Second Quarter 2021 Financial Results and Corporate Progress
August 10, 2021 16:05 ET
|
Day One Biopharmaceuticals, Inc.
DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission Dosed the First Patients in Pivotal FIREFLY-1 Clinical Trial of DAY101 in...
Day One Biopharmaceuticals to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2021 08:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma
July 27, 2021 07:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma
June 21, 2021 07:00 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies...
Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 01, 2021 16:01 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...
Day One Announces Pricing of Upsized Initial Public Offering
May 26, 2021 22:30 ET
|
Day One Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing...